Brief: Vicore Pharma Q4 EBIT SEK -120.6 Million
28/02/2024 07:00
Feb 28 (Reuters) - Vicore Pharma Q4 adjusted EPS SEK -1. * Q4 net income SEK -111.9 million * Q4 adjusted free cash flow SEK -67.5 million * Q4 sales SEK 0 * Q4 cash & investments SEK 482.8 million
Recent news on Vicore Pharma Holding AB
See all newsBrief: Vicore Pharma Holding Q3 Net Revenues Amounted To Sek 0.6 Mln
Brief: Vicore Pharma Holding AB Phase 2B Aspire Trial Of Buloxibutid In Ipf Passes Pre-Planned Futility Analysis, On Track For Mid-2027 Topline Results
Brief: Vicore Pharma Q2 Operating Loss At SEK 150.1 Million
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:53 PM
Brief: Vicore Pharma Shares Start Trading In US On July 2